RHOT1 and asthma: Collectively, we have demonstrated the therapeutic efficacy of EPO-BM-MSCs, with the ability to rescue epithelial cell injury by mitochondrial donation by upregulating HO-1, M-sec, and Miro1, in asthma inflammation (Fig. 7).